Application note: A Simoa™ Bridging Assay for Anti Drug Antibody Detection
Posted: 26 November 2019 | Quanterix | No comments yet
Therapeutic drugs based on biological materials (antibodies, hormones, cytokines, enzymes, fusion proteins) may have the ability to elicit an immune response in the host.
Immunogenicity of a therapeutic is defined as the unwanted elicitation of an immune response by the host to the therapeutic. The measurement of this immune response is typically assessed by quantifying the host’s production of antibodies against the therapeutic molecule. Immunogenicity of a therapeutic can be a major roadblock in the development of a product.
Here, we describe a proof of concept assay to demonstrate use of the Simoa platform as a tool to measure levels of anti drug antibodies ( against Adalimumab (Humira®). To compare performance, equivalent assays were run with the Simoa platform and a standard plate based ELISA.
Related content from this organisation
- Application note: A Simoa™ Bridging Assay for Anti Drug Antibody Detection
- Application note: A Simoa ™ Pharmacokinetic Bridging Assay
- Application note: Cell Lysate Sample Handling with Simoa Bead-Based Assays
- Application note: Analysis of Inflammatory Plasma Biomarkers in Cancer Patient Samples
Antibodies, Assays, Immunogenicity, Screening, Therapeutics